Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus THORAZINE.
HALOPERIDOL DECANOATE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol decanoate is a long-acting ester prodrug of haloperidol, a typical antipsychotic. Haloperidol acts primarily as a dopamine D2 receptor antagonist in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits affinity for D1, D3, D4, sigma, and 5-HT2 receptors, but its antipsychotic efficacy is primarily attributed to D2 blockade.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
100-200 mg intramuscular deep injection every 4 weeks. Maximum 450 mg per month.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life of haloperidol decanoate: approximately 3 weeks (range 14-28 days) due to slow release from depot and subsequent de-esterification. Steady-state achieved after 3-4 monthly doses.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Renal: 40% (as metabolites; <1% unchanged); Fecal: 60% (primarily via biliary elimination).
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic